Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and-independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3

Prostate

Volumn 72, Issue 4, 2012, Pages 361-375

  Aghaei, Mahmoud ^a   Karami Tehrani, Fatemeh ^a   Panjehpour, Mojtaba ^b   Salami, Siamak ^c   Fallahian, Faranak ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

adenosine; apoptosis; prostate cancer

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ANDROGEN; BROXURIDINE; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOSINE; ANDROGENS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, PURINERGIC P1;

EID: 84856031113     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21438     Document Type: Article

References (71)

1. Boring CC, Squires TS, Tong T,. Cancer statistics. CA Cancer J Clin 1991; 41: 19-36.
2. Sufrin G, Coffey DS,. Flutamide: Mechanisms of action of a new nonsteroidal antiandrogen. Invest Urol 1976; 13: 429-434.
3. Redding TW, Schally AV,. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. Prostate 1985; 6: 219-232. (Pubitemid 15111832)
4. Eisenberger MA, O'Dwyer PJ, Friedman MA,. Gonadotropinhormone-releasing hormone analogues: A new therapeutic approach for prostatic cancer. J Clin Oncol 1986; 4: 414-424. (Pubitemid 16133096)
5. Labrie F, Dupont A, Belanger A,. Complete androgen blockade for the treatment of prostate cancer. In:, DeVita VT, Hellman S, Rosenberg SA, editors Important advances in oncology. Philadelphia: J B Lippincott Co.; 1985. pp. 193-217.
6. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424. (Pubitemid 19211484)
7. Scott WW, Menon M, Walsh PC,. Hormonal therapy of prostatic cancer. Cancer 1980; 45: 1929-1936. (Pubitemid 10153645)
8. Isaacs JT, Schulze H, Coffey DS,. Development of androgen resistance in prostatic cancer. In:, Murphy GP, Khoury S, Kuss IR, Chatelain C, Denis L, editors. In prostate cancer, part A: Research, endocrine treatment, histopathology. New York: Alan R. Liss, Inc.; pp. 21-31.
9. Anglin IE, Glassman D, Kyprianou TN,. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: Mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002; 5: 88-95. (Pubitemid 34777889)
10. Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA,. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 2002; 13: 781-790.
11. Fang WG, Pirnia F, Bang YJ, Myers CE, Trepel JB,. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J Clin Invest 1992; 89 (1): 191-196.
12. Kim JH, Nam JH, Kim MH, Koh DS, Choi SJ, Kim SJ, Lee JE, Min KM, Uhm DY, Kim SJ,. Purinergic receptors coupled to intracellular Ca2-Signals and exocytosis in rat prostate neuroendocrine cells. J Biol Chem 2004; 279 (26): 27345-27356. (Pubitemid 38812574)
13. Janssens R, Boeynaems JM,. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol 2001; 132 (2): 536-546. (Pubitemid 32142367)
14. Olah ME, Stiles GL,. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995; 35: 581-606.
15. Guijarro LG, Juarranz MG, Marinero MJ, Pajuelo L, Carmena MJ, Prieto JC,. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: Role in prostatic proliferation. Ann NY Acad Sci 1996; 805: 723-728. (Pubitemid 27058085)
16. Panjehpour M, Karami-Tehrani F,. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 2007; 16 (12): 575-585. (Pubitemid 351344780)
17. Spychala J,. Tumor-promoting functions of adenosine. Pharmacol Ther 2000; 87: 161-173.
18. Baines CP, Cohen MV, Downey JM,. Signal transduction in ischemic preconditioning: The role of kinases and mitochondrial K(ATP) channels. J Cardiovasc Electrophysiol 1999; 10: 741-754. (Pubitemid 29227818)
19. Fredholm BB,. Purinoceptors in the nervous system. Pharmacol Toxicol 1995; 76: 228-239.
20. Fredholm BB,. Adenosine neuroprotection. Int Rev Neurobiol 1997; 40: 259-280.
21. Sebastiao AM, Ribeiro JA,. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996; 48: 167-189. (Pubitemid 26161859)
22. Haas HL, Selbach O,. Functions of neuronal adenosine receptors. Naunyn Schmiedeberg's Arch Pharmacol 2000; 362: 375-381.
23. Sawynok J,. Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347: 1-11. (Pubitemid 28238080)
24. Sawynok J,. Purines in pain management. Curr Opin CPNS Investig Drugs 1999; 1: 27-38.
25. Roman RM, Fitz JG,. Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Gastroenterology 1999; 116: 964-979. (Pubitemid 29153546)
26. Cronstein BN,. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76: 5-13. (Pubitemid 24048220)
27. Linden J,. Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994; 15: 298-306.
28. Marquardt DL,. Mast cell adenosine receptor characteristics and signaling. Adv Exp Med Biol 1998; 431: 79-82. (Pubitemid 28236743)
29. Forsythe P, Ennis M,. Adenosine, mast cells and asthma. Inflamm Res 1999; 48: 301-307. (Pubitemid 29329291)
30. Burnstock G,. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22: 364-373. (Pubitemid 34218740)
31. Abbracchio MP, Ceruti S, Brambilla R, Franceschi C, Malorni W, Jacobson KA, von Lubitz DK, Cattabeni F,. Modulation of apoptosis by adenosine in the central nervous system: A possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann NY Acad Sci 1997; 825: 11-22. (Pubitemid 27506421)
32. Ohana G, Bar-Yehuda S, Barer F, Fishman P,. Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. J Cell Physiol 2001; 186: 19-23.
33. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E, Mac Lennan S, Feo C, Baraldi S, Borea PA,. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A (3) adenosine subtype. J Cell Physiol 2007; 211 (3): 826-836. (Pubitemid 46683050)
34. Tanaka Y, Yoshihara K, Tsuyuki M, Kamiya T,. Apoptosis induced by adenosine in human leukemia HL-60 cells. Exp Cell Res 1994; 213 (1): 242-252. (Pubitemid 24227406)
35. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, Borea PA,. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 2002; 119 (4): 923-933. (Pubitemid 35340920)
36. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J,. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53 (4): 527-552. (Pubitemid 33136237)
37. Poulsen SA, Quinn RJ,. Adenosine receptors: New opportunities for future drugs. Bioorg Med Chem 1998; 6: 619-641. (Pubitemid 28287266)
38. Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F,. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: The role of ROS and the effect of metal ions. J Leuk Biol 2004; 76: 169-175. (Pubitemid 38857184)
39. Schorl C, Sedivy JM,. Analysis of cell cycle phases and progression in cultured mammalian cells. Methods 2007; 41: 143-150. (Pubitemid 44960829)
40. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M,. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP-kinase dependent pathway. J Leukoc Biol 2008; 83: 1484-1492. (Pubitemid 351960330)
41. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C,. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
42. Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, McNeill KD, Hashemi M, Kerkhoff C, Los M,. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res 2010; 20: 314-331.
43. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, Hashemi M, Eshraghi M, Schulze-Osthoff K, Klonisch T, Los M,. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta 2008; 1783: 297-311.
44. Meininger CJ, Schelling ME, Granger HJ,. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am J Physiol 1988; 255 (3): 554-562.
45. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L,. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci 2001; 42 (9): 2068-2073. (Pubitemid 32726041)
46. Abbracchio MP, Camurri A, Ceruti S, Cattabeni F, Falzano L, Giammarioli AM, Jacobson KA, Trincavelli L, Martini C, Malorni W, Fiorentini C,. The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. Ann NY Acad Sci 2001; 939: 63-73. (Pubitemid 32620056)
47. Jin S, Mazzacurati L, Zhu X, Tong T, Song Y, Shujuan S, Petrik KL, Rajasekaran B, Wu M, Zhan Q,. Gadd45a contributes to p53 stabilization in response to DNA damage. Oncogene 2003; 22: 8536-8540. (Pubitemid 37523906)
48. Kim SY, Kim JE, Lee KW, Lee HJ,. Lactococcus lactis ssp. lactis inhibits the proliferation of SNU-1 human stomach cancer cells through induction of G0/G1 cell cycle arrest and apoptosis via p53 and p21 expression. Ann NY Acad Sci 2009; 1171: 270-275.
49. Al-Mohanna MA, Al-Khodairy FM, Krezolek Z, Bertilsson PA, Al-Houssein KA, Aboussekhra A,. p53 is dispensable for UV-induced cell cycle arrest at late G(1) in mammalian cells. Carcinogenesis 2001; 22: 573-578. (Pubitemid 32288657)
50. Cory S, Adams JM,. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656. (Pubitemid 37328916)
51. Wu LF, Li GP, Su JD, Pu ZJ, Feng JL, Ye YQ, Wei BL,. Involvement of NF-kappaB activation in the apoptosis induced by extracellular adenosine in human hepatocellular carcinoma HepG2cells. Biochem Cell Biol 2010; 88: 705-714.
52. Le Bras M, Clément MV, Pervaiz S, Brenner C,. Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol Histopathol 2005; 20: 205-219.
53. Sai K, Yang D, Yamamoto H, Fujikawa H, Yamamoto S, Nagata T, Saito M, Yamamura T, Nishizaki T,. A(1) adenosine receptor signal and AMPK involving caspase-9/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma cell death. Neurotoxicology 2006; 27: 458-467. (Pubitemid 43867776)
54. Wu LF, Li GP, Feng JL, Pu ZJ,. Molecular mechanisms of adenosine-induced apoptosis in human HepG2 cells. Acta Pharmacol Sin 2006; 27: 477-484.
55. El-Darahali A, Fawcett H, Mader JS, Conrad DM, Hoskin DW,. Adenosine-induced apoptosis in EL-4 thymoma cells is caspase-independent and mediated through a non-classical adenosine receptor. Exp Mol Pathol 2005; 79: 249-258. (Pubitemid 41568617)
56. Zhang YX, Yu SB, Ou-Yang JP, Xia D, Wang M, Li JR,. Effect of protein kinase C alpha, caspase-3, and survivin on apoptosis of oral cancer cells induced by staurosporine. Acta Pharmacol Sin 2005; 26: 1365-1372. (Pubitemid 41607010)
57. Kang CM, Sun Y, Jang IS, Park SC,. Thymidine-dependent attenuation of the mitochondrial apoptotic pathway in adenosine induced apoptosis of HL-60 cell. J Cancer Res Clin Oncol 2001; 12: 570-576.
58. Tai CJ, Chang SJ, Chien LY, Leung PC, Tzeng CR,. Adenosine triphosphate induces activation of caspase-3 in apoptosis of human granulosa-luteal cells. Endocr J 2005; 52: 327-335. (Pubitemid 41003524)
59. Corbiere C, Liagre B, Terro F, Beneytout JL,. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res 2004; 14: 188-196. (Pubitemid 43231816)
60. Saito M, Yaguchi T, Yasuda Y, Nakano T, Nishizaki T,. Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A1 adenosine receptors. Cancer Lett 2010; 290: 211-215.
61. Shieh DE, Chen YY, Yen MH, Chiang LC, Lin CC,. Emodininduced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci 2004; 74: 2279-2290.
62. Schneider C, Wiendl H, Ogilive A,. Biophasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: Involvement of adenosine generation. Biochim Biophys Acta 2001; 1538: 190-205. (Pubitemid 32402242)
63. Di Iorio P, Kleywegt S, Ciccarelli R, Traversa U, Andrew CM, Crocker CE, erstiuk ES, Rathbone MP,. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 2002; 38: 179-190.
64. Kim KT, Yeo EJ, Choi H, Park SC,. The effect of pyrimidine nucleosides on adenosine-induced apoptosis in HL-60cells. Cancer Res Clin Oncol 1998; 24: 471-477. (Pubitemid 28474156)
65. Atey HB, Tan CH, Khoo HE,. Modulation of DNA synthesis via adenosine receptors in human epidermoid carcinoma (A431) cells. Biofactors 1994; 4: 161-165.
66. Peyot ML, Gadeau AP, Dandre F, Belloc I, Dupuch F, Desgrane C,. Extracellular adenosine induces apoptosis in human arterial smooth muscle cells via A2b-purioceptor. Circ Res 2000; 86: 76-85. (Pubitemid 30044171)
67. Kurland JI, Hadden JW, Moore MAS,. Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res 1977; 37: 4534-4538. (Pubitemid 8239660)
68. Ward AC, Csar XF, Hoffmann BW, Hamilton JA,. Cyclic AMP inhibits expression of D-type cyclins and cdk4 and induces p27kip1in G-CSF-treated NFS-60cells. Biochem Biophys Res Commun 1996; 224: 10-16. (Pubitemid 26252403)
69. Skålhegg BS, Johansen AK, Levy FO, Andersson KB, Aandahl EM, Blomhoff HK, Hansson V, Taskén K,. Isozymes of cyclic AMP-dependent protein kinases (PKA) in human lymphoid cell lines: Levels of endogenous cAMP influence levels of PKA subunits and growth in lymphoid cell lines. J Cell Physiol 1998; 177: 85-93. (Pubitemid 28421524)
70. Rayhel EJ, Hughes JP, Svihla DA, Prentice DA,. Growth and protein phosphorylation in the Nb2 lymphoma: Effect of prolactin, cAMP, and agents that activate adenylate cyclase. J Cell Biochem 1990; 43: 327-337. (Pubitemid 20250715)
71. Fishman P, Yehuda SB, Ohana G, Pathak S, Wasserman L, Barer F, Multani AS,. Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A3 adenosine receptor. Eur J Cancer 2000; 36: 1452-1458. (Pubitemid 30421151)